US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Articles published by Affimed N.V.

< Previous 1 2 Next >
News headline image
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Announces Leadership Change and Organizational Restructuring
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed to Participate in Upcoming Investor Conferences
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Announces Listing Transfer to Nasdaq Capital Markets
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed to Present at the Cantor Global Healthcare Conference 2023
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed to Present at the H.C. Wainwright Annual Global Investment Conference
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech’s SNK01 NK Cells
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed to Present at the 2023 Jefferies Healthcare Conference
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed Announces Annual General Meeting of Shareholders
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
News headline image
Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
< Previous 1 2 Next >